• SPX
  • $5,917.11
  • 0 %
  • $0.13
  • DJI
  • $43,408.47
  • 0.32 %
  • $139.53
  • N225
  • $38,026.17
  • -0.85 %
  • -$326.17
  • FTSE
  • $8,110.57
  • 0.32 %
  • $25.50
  • IXIC
  • $18,966.14
  • -0.11 %
  • -$21.33
Regeneron Pharmaceuticals, Inc. (REGN) Stock Price, News & Analysis

Regeneron Pharmaceuticals, Inc. (REGN) Stock Price, News & Analysis

Currency in USD Disclaimer

$743.29

-$1.31

(-0.18%)

Day's range
$736.01
Day's range
$750.69
50-day range
$736.01
Day's range
$1170.58
  • Country: US
  • ISIN: US75886F1075
52 wk range
$736.01
Day's range
$1211.2
  • CEO: Dr. Leonard S. Schleifer M.D., Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 8.35
  • Piotroski Score 4.00
  • Grade Outperform
  • Symbol (REGN)
  • Company Regeneron Pharmaceuticals, Inc.
  • Price $743.29
  • Changes Percentage (-0.18%)
  • Change -$1.31
  • Day Low $736.01
  • Day High $750.69
  • Year High $1,211.20

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 01/31/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $1,055.00
  • High Stock Price Target $1,292.00
  • Low Stock Price Target $604.00
  • Potential Upside/Downside N/A
  • Consensus Rating Buy
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) $33.83
  • Trailing P/E Ratio 29.65
  • Forward P/E Ratio 29.65
  • P/E Growth 29.65
  • Net Income $3.95 B

Income Statement

Quarterly

Annual

Latest News of REGN

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Regeneron Pharmaceuticals, Inc. Frequently Asked Questions

  • What were the earnings of REGN in the last quarter?

    In the last quarter Regeneron Pharmaceuticals, Inc. earnings were on Thursday, October, 31st. The Regeneron Pharmaceuticals, Inc. maker reported $12.46 EPS for the quarter, beating analysts' consensus estimates of $11.69 by $0.77.

  • What is the Regeneron Pharmaceuticals, Inc. stock price today?

    Today's price of Regeneron Pharmaceuticals, Inc. is $743.29 — it has decreased by -0.18% in the past 24 hours. Watch Regeneron Pharmaceuticals, Inc. stock price performance more closely on the chart.

  • Does Regeneron Pharmaceuticals, Inc. release reports?

    Yes, you can track Regeneron Pharmaceuticals, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Regeneron Pharmaceuticals, Inc. stock forecast?

    Watch the Regeneron Pharmaceuticals, Inc. chart and read a more detailed Regeneron Pharmaceuticals, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Regeneron Pharmaceuticals, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Regeneron Pharmaceuticals, Inc. stock ticker.

  • How to buy Regeneron Pharmaceuticals, Inc. stocks?

    Like other stocks, REGN shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Regeneron Pharmaceuticals, Inc.'s EBITDA?

    Regeneron Pharmaceuticals, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Regeneron Pharmaceuticals, Inc.’s financial statements.

  • What is the Regeneron Pharmaceuticals, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is 0.3014057878, which equates to approximately 30.14%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Regeneron Pharmaceuticals, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Regeneron Pharmaceuticals, Inc.'s financials relevant news, and technical analysis. Regeneron Pharmaceuticals, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Regeneron Pharmaceuticals, Inc. stock currently indicates a “sell” signal. For more insights, review Regeneron Pharmaceuticals, Inc.’s technical analysis.

  • A revenue figure for Regeneron Pharmaceuticals, Inc. for its last quarter?

    Regeneron Pharmaceuticals, Inc. published it's last quarterly revenues at $3.72 B.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.